Neil Mehta1, Julie Heimbach, David Lee, Jennifer L Dodge, Denise Harnois, Justin Burns, William Sanchez, John P Roberts, Francis Y Yao. 1. 1 Division of Gastroenterology, Department of Medicine, University of California, San Francisco, CA. 2 Division of Transplantation, Department of Surgery, Mayo Clinic, Rochester, MN. 3 Department of Transplantation, Mayo Clinic, Jacksonville, FL. 4 Division of Transplant Surgery, Department of Surgery, University of California, San Francisco, CA. 5 Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Abstract
BACKGROUND: It has been postulated that short wait time before liver transplant (LT) for hepatocellular carcinoma (HCC) results in the inclusion of tumors with aggressive biology, but prolonged wait time could result in a shift to more aggressive tumor behavior. We therefore test the hypothesis that a wait time "sweet spot" exists with a lower risk for HCC recurrence compared with the other 2 extremes. METHODS: This multicenter study included 911 patients from 3 LT centers with short, medium, and long wait times (median of 4, 7, and 13 months, respectively) who received Model for End Stage Liver Disease exception listing for HCC from 2002 to 2012. RESULTS: Wait time, defined as time from initial HCC diagnosis to LT, was less than 6 months in 32.4%, 6 to 18 months in 53.7%, and greater than 18 months in 13.9%. Waitlist dropout was observed in 18.4% at a median of 11.3 months. Probability of HCC recurrence at 1 and 5 years were 6.4% and 15.5% with wait time of less than 6 or greater than 18 months (n = 343) versus 4.5% and 9.8% with wait time of 6 to 18 months (n = 397), respectively (P = 0.049). When only pre-LT factors were considered, wait time of less than 6 or greater than 18 months (HR, 1.6; P = 0.043) and AFP greater than 400 at HCC diagnosis (HR, 3.0; P < 0.001) predicted HCC recurrence in multivariable analysis. CONCLUSIONS: This large multicenter study provides evidence of an association between very short (<6 months) or very long (>18 months) wait times and an increased risk for HCC recurrence post-LT. The so-called sweet spot of 6 to 18 months should be the target to minimize HCC recurrence.
BACKGROUND: It has been postulated that short wait time before liver transplant (LT) for hepatocellular carcinoma (HCC) results in the inclusion of tumors with aggressive biology, but prolonged wait time could result in a shift to more aggressive tumor behavior. We therefore test the hypothesis that a wait time "sweet spot" exists with a lower risk for HCC recurrence compared with the other 2 extremes. METHODS: This multicenter study included 911 patients from 3 LT centers with short, medium, and long wait times (median of 4, 7, and 13 months, respectively) who received Model for End Stage Liver Disease exception listing for HCC from 2002 to 2012. RESULTS: Wait time, defined as time from initial HCC diagnosis to LT, was less than 6 months in 32.4%, 6 to 18 months in 53.7%, and greater than 18 months in 13.9%. Waitlist dropout was observed in 18.4% at a median of 11.3 months. Probability of HCC recurrence at 1 and 5 years were 6.4% and 15.5% with wait time of less than 6 or greater than 18 months (n = 343) versus 4.5% and 9.8% with wait time of 6 to 18 months (n = 397), respectively (P = 0.049). When only pre-LT factors were considered, wait time of less than 6 or greater than 18 months (HR, 1.6; P = 0.043) and AFP greater than 400 at HCC diagnosis (HR, 3.0; P < 0.001) predicted HCC recurrence in multivariable analysis. CONCLUSIONS: This large multicenter study provides evidence of an association between very short (<6 months) or very long (>18 months) wait times and an increased risk for HCC recurrence post-LT. The so-called sweet spot of 6 to 18 months should be the target to minimize HCC recurrence.
Authors: Karim J Halazun; Rachel E Patzer; Abbas A Rana; Elizabeth C Verna; Adam D Griesemer; Ronald F Parsons; Benjamin Samstein; James V Guarrera; Tomoaki Kato; Robert S Brown; Jean C Emond Journal: Hepatology Date: 2014-09-10 Impact factor: 17.425
Authors: Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton Journal: Liver Transpl Date: 2006-08 Impact factor: 5.799
Authors: John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: Johann von Felden; Denise Heim; Kornelius Schulze; Till Krech; Florian Ewald; Björn Nashan; Ansgar W Lohse; Henning Wege Journal: BMC Cancer Date: 2017-01-18 Impact factor: 4.430
Authors: Markus Bo Schoenberg; Hubertus Johann Wolfgang Anger; Julian Nikolaus Bucher; Gerald Denk; Enrico Narciso De Toni; Max Seidensticker; Joachim Andrassy; Martin Kurt Angele; Jens Werner; Markus Otto Guba Journal: Visc Med Date: 2020-03-20
Authors: Max N Brondfield; Jennifer L Dodge; Ryutaro Hirose; Julie Heimbach; Francis Y Yao; Neil Mehta Journal: Liver Transpl Date: 2020-05 Impact factor: 5.799